News
Oryzon raises "12m to push AML and CNS pipeline - European Biotechnology Magazine
57+ min ago (427+ words) Spanish epigenetics biotech Oryzon Genomics has raised "12m in a capital increase and signed a financing agreement with COFIDES that could add another "25m in future share subscriptions. Why it matters: The Barcelona-based company is trying to keep momentum behind two clinical-stage…...
Telum raises "18 M to push phage-derived antimicrobials toward clinic - European Biotechnology Magazine
6+ hour, 58+ min ago (386+ words) Spanish biotech Telum Therapeutics has raised "18 million in Series A financing to move its lead antimicrobial programme toward clinical development. Zoom in: The round was led by AMR Action Fund, with participation from new investor Inveready and existing backers Invivo…...
Abivax cashes in on investor enthusiasm with "807m raise - European Biotechnology Magazine
8+ hour, 14+ min ago (377+ words) Abivax has raised $920m (807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug's safety profile in ulcerative colitis. Why it matters: The financing gives the French biotech a much…...
Alze Cure licenses Alzheimer's asset to Quantum Cell in $2. 2bn deal - European Biotechnology Magazine
23+ hour, 57+ min ago (463+ words) Swedish biotech Alze Cure Pharma has licensed global rights to its Neuro Restore platform, including lead Alzheimer's candidate ACD856, to Danish biotech Quantum Cell Ap S in a deal worth more than $2. 2bn, excluding royalties. Why it matters: The agreement gives Alze…...
Ipsen's buying streak continues with "700m Memo deal - European Biotechnology Magazine
1+ day, 6+ hour ago (535+ words) Paris-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than "700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeline. Why it matters: It is Ipsen's second acquisition in a week, following…...
smartbax extends pre-series A to "6. 3 m for new antibiotic - European Biotechnology Magazine
2+ day, 1+ hour ago (385+ words) Munich-based smartbax has secured additional financing to advance its lead antibiotic programme, building on a "4. 7m pre-Series A first close announced in October 2025. Why it matters: The company is working in one of biotech's toughest markets: new antibiotics. Its lead programme…...
Scancell plots reverse-merger path to Nasdaq - European Biotechnology Magazine
2+ day, 8+ hour ago (425+ words) UK immunotherapy developer Scancell has confirmed talks to acquire Nasdaq-listed Neuphoria Therapeutics, in a move that could give the Oxford-based biotech a faster route to US public markets. Why it matters: For Scancell, the strategic value appears less about Neuphoria's…...
Abivax answers safety questions with new data - European Biotechnology Magazine
2+ day, 5+ hour ago (523+ words) Abivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing later this year. Why it matters: The new readout follows a…...
8 European VC firms to watch in 2026 - European Biotechnology Magazine
3+ day, 3+ hour ago (385+ words) This is the backdrop against which Europe's biotech VCs matter more than ever. In a market where capital is scarcer, the identity of the investor becomes part of the company's strategy. The best firms are not simply writing cheques. They…...
The connective matrix: ELRIG's role in the drug discovery ecosystem - European Biotechnology Magazine
3+ day, 8+ hour ago (457+ words) A defining feature of ELRIG's programming model is its distinction between conferences and forums. Conferences are designed for breadth: large gatherings that surface emerging themes and bring the wider community into contact. Forums are intentionally smaller and more focused, convened…...